Iqvia Holdings Inc. IQV 0.83% is hardly a household name, but its boss made more last year than the chief executive of Johnson & Johnson —or any other big pharmaceutical or biotech company.
Iqvia doesn’t have some blockbuster drug or cutting-edge genetic treatment. It is a data company that collects prescription sales, medical claims and other patient records, and analyzes that information for drugmakers, insurance companies and governments. It also provides testing services to drug companies.
Last year, the Durham, N.C., company paid its CEO, Ari Bousbib, $38 million. J&J, the largest U.S. pharmaceutical company by revenue, paid its CEO, Alex Gorsky, $29.8 million in 2017. J&J had about $76 billion in revenue in 2017, Iqvia’s was about $8 billion.
The two companies delivered similar shareholder gains last year. J&J’s stock-price appreciation plus dividends returned 24.4% to investors, while the smaller company returned 28.7%.
Nearly 40 S&P 500 firms included security costs in their CEOs' perk packages last year,…
Within the next five years, major corporations from JPMorgan Chase to The Walt Disney Co.…
Artificial intelligence is the single-largest area that boards have devoted time to in the last…
The chiefs of America’s biggest companies reached new pay heights in 2023 as stock awards…
Elon Musk didn’t just upend the global auto business and space missions. The billionaire is…
In 2023, the leaders of America's largest companies saw their compensation packages soar to unprecedented…